CELLINK AB Acquires MatTek Corporation
March 22, 2021
CELLINK AB (publ) acquired MatTek Corporation, a U.S. developer of advanced in‑vitro 3D human tissue models, completing the transaction on March 22, 2021 for approximately USD 72 million (including adjustments). The consideration included ~USD 13.6 million paid in newly issued CELLINK series B shares with the remainder paid in cash; Fairmount Partners advised MatTek on the sale.
- Buyers
- CELLINK AB
- Targets
- MatTek Corporation
- Industry
- Biotechnology
- Location
- Massachusetts, United States
- Transaction Type
- Buyout
Explore More
Related Acquisitions
-
Thermo Fisher Scientific Acquires Olink Holding AB
July 10, 2024
Biotechnology
Thermo Fisher Scientific completed the acquisition of Olink Holding AB (publ) via a public cash tender offer at USD 26.00 per share/ADS, buying the proteomics company from shareholders including Summa Equity. The acquisition strengthens Thermo Fisher’s proteomics and protein-analysis capabilities, adding Olink’s high‑multiplex protein detection technology to its life‑science tools portfolio.
-
Integra LifeSciences Acquires ACell, Inc.
December 16, 2020
Medical Devices
Integra LifeSciences agreed to acquire regenerative-medicine company ACell, Inc. for $300 million upfront in cash plus up to $100 million in revenue-based milestones. The acquisition adds ACell's MatriStem porcine urinary bladder matrix platform to Integra's tissue technologies portfolio and is expected to close in Q1 2021, subject to customary conditions.
-
Miltenyi Biotec Acquires lino Biotech
March 22, 2023
Biotechnology
Miltenyi Biotec has acquired 100% of lino Biotech from investors including Roche Venture Fund and Hightech-Grunderfonds. The acquisition brings lino's focal molography biosensor platform into Miltenyi's cell and gene therapy and research-tools portfolio to enhance potency assays and quality-control capabilities.
-
AnaBios Acquires Cell Systems
April 4, 2023
Biotechnology
AnaBios Corporation has acquired Cell Systems, a Kirkland, Washington supplier of human primary cells and cell culture media, to expand its human tissue and cell portfolio and accelerate translational drug discovery. Financing for the transaction was provided by AnaBios' existing investors, including Ampersand Capital Partners; financial terms were not disclosed.
-
BioIVT Acquires XenoTech from Sekisui Chemical
September 12, 2022
Biotechnology
BioIVT has acquired XenoTech, a Kansas City–based provider of ADME‑Tox in vitro models and contract research services, from Sekisui Chemical. The acquisition expands BioIVT's hepatic product portfolio and ADME/DMPK capabilities to better support biopharma customers' preclinical testing needs. Financial terms were not disclosed.
-
Bio-Techne Acquires Namocell
June 22, 2022
Medical Devices
Bio-Techne Corporation has agreed to acquire Namocell, Inc., a Mountain View–based provider of single-cell sorting and dispensing platforms, with the deal expected to close in Bio-Techne's fiscal 2023 Q1. Namocell's Pala and Hana systems (installed base approaching 200 placements, ~60 sold in 2021) will complement Bio-Techne's Cell and Gene Therapy franchise and create commercial synergies across its analytical instruments sales force.
Track M&A activity that matters to you
Get real-time deal alerts, build buyer lists with AI, and access our full acquisition database. Start your free trial today.